Tennessee Lawyers Offer Free Case Evaluation on Raptiva
November 9, 2009 · Print This Article
The FDA and pharmaceutical manufacturer Genentech have notified consumers and healthcare professionals of the phased withdrawal of the psoriasis medication Raptiva from the U.S. market over potential progressive multifocal leukoencephalopathy (PML), a rare brain infection. While this is not a recall of Raptiva, patients taking the drug should notify their physician and discuss switching to an alternative treatment. Physicians are being asked not initiate Raptiva treatment for any new patients.
In February of 2009 the FDA issued a Public Health Advisory to notify health care providers of three confirmed occurrences of PML in patients taking Raptiva. Last October the administration amended the label of Raptiva with a boxed warning highlighting the potential risk life-threatening infections, including PML. The complete removal of the medication from the U.S. market is expected to be completed by June 8, 2009.
If you or a loved one has taken the prescription medication Raptiva and have experienced have developed progressive multifocal leukoencephalopathy (PML), we may be able to help. We are providing free case evaluations to you.
Let us put our experience and expertise to work for you. We are currently helping others who have received a defective Advanced Bionics cochlear implant, Transvaginal mesh/sling devices, or took prescription drugs such as Trasylol, Chantix, Digitek, Byetta, Ortho Evra, Seroquel, Reglan, and Yaz/Yasmin. We also handle medical malpractice claims.
Tim Edwards
Ed Wallis
Glassman, Edwards, Wade & Wyatt, PC
26 N. 2nd Street
Memphis, TN 38103
(901) 527-2125
(901) 275-0600 (after hours, weekends)
EMAIL BY CLICKING HERE
Free Case Evaluation Form:








Comments
Got something to say?